Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Oct 27 (Reuters) - BASILEA PHARMACEUTICA AG, ALLSCHWIL BSLN.S:
RAISES FULL-YEAR GUIDANCE 2026 AND FINANCIAL TARGET FOR “AGENDA 2030” AND PROVIDES UPDATES ON LATE-STAGE CLINICAL PROGRAMS
2026 OPERATING PROFIT EXPECTED TO REACH CHF 115 MILLION
RAISES FINANCIAL GUIDANCE FOR FY2026 AND CASH FLOW TARGET FOR 2026-2030
FY2026 RESEARCH AND DEVELOPMENT EXPENSES GUIDANCE CHF 125 MILLION; OPERATING PROFIT GUIDANCE CHF 115 MILLION
OUTLOOK 2026: EXPECTS TOTAL REVENUE AROUND CHF 310 MILLION
Further company coverage: BSLN.S